End-of-Year Platform Update: Advancing Governance and Buy-Side Preparation
UNI Venture Group advances international, sovereign-aligned pharmaceutical manufacturing platforms across the U.S. and partner jurisdictions, with active work-streams focused on governance, financing, and regulatory sequencing. As we enter 2026, the platform is entering preparatory stages for the next phase of its buy-side process. Select industry participants have been notified of evolving developments, and broader formal engagement will follow the completion of governance and structural milestones. This update reflects an end-of-year progress update following prior public disclosures related to this initiative. Happy New Year.
IBI-Tech and Peixe Rosa Program Aligned to Advance Biotech Collaboration
Strengthening Ties Between Israel and Brazil in Life Sciences and R&D IBI-Tech has formally expressed its intent on collaborating with the Peixe Rosa Program to bridge Israel’s cutting-edge biotech innovation with Brazil’s expanding life sciences sector. With over a decade of experience connecting Israel’s R&D capabilities with the Brazilian market, IBI-Tech aims to enhance the region’s biotech ecosystem through strategic scouting and investment. This collaboration will focus on identifying promising Israeli technologies, startups, and R&D programs that align with Brazil’s healthcare and pharmaceutical needs. The initiative will also highlight Brazil as an attractive destination for global entrepreneurs and biotech innovators. IBI-Tech and the Peixe Rosa Program will work closely to define commercial terms and implement a framework that fosters investment, innovation, and growth. This partnership will serve as a catalyst for technological advancements, further solidifying Brazil’s position in the global biotech industry while strengthening Israel-Brazil relations in science and medicine.
U.S. Visionary Leadership and Feasibility Investments Toward Brazil’s Biopharmaceutical Advancements
Collaborative Efforts Drive Innovation and Economic Growth The Partnership for Productive Development (PDP) pathway explored through the Peixe Rosa Program reflects an early-stage, exploratory effort to evaluate mechanisms for strengthening Brazil’s domestic biopharmaceutical manufacturing capacity. The initiative has been informed by input from experienced industry professionals across governance, finance, and technical domains, as part of a broader assessment of viable public–private collaboration models. In parallel, the project architects have been evaluating potential long-term capital structures, including the concept of an investment platform intended to support infrastructure development, technology transfer, and market expansion, subject to regulatory alignment, institutional participation, and appropriate sequencing. These exploratory efforts are intended to inform future pathways for international collaboration in Latin America’s life sciences sector, including potential market entry strategies, research collaboration, and capital markets engagement, where appropriate. The initiative continues to evolve as part of a broader, multi-jurisdictional platform strategy.
Evaluating Acquisition Pathways for API Manufacturing and Industrial Capacity
Strategic Capital Markets Paths to Revolutionize Brazil’s API Industry As part of its broader platform development efforts, the initiative has evaluated multiple strategic pathways for strengthening active pharmaceutical ingredient (API) manufacturing capabilities, including organic development models, technology transfer frameworks, and potential acquisition scenarios. These evaluations were conducted at a conceptual level to understand how existing industrial assets, human capital, and technological capabilities might be integrated into a resilient manufacturing platform aligned with national health priorities and international supply-chain considerations. Discussions during this phase focused on early governance structures, regulatory alignment, and long-term sustainability . Any potential acquisition or industrial integration remains subject to further diligence, institutional alignment, and appropriate sequencing within a broader platform strategy. This exploratory work contributed to a deeper understanding of the structural challenges facing API supply chains and informed subsequent decisions to pursue a more diversified, multi-jurisdictional approach to pharmaceutical manufacturing and investment.
Peixe Rosa Program: A Vision for Transforming Latin America’s Biopharmaceutical Landscape
Driving Innovation in Life Sciences Through Research, Collaboration, and Investment Launched in 2016, the Peixe Rosa Program is a transformative initiative designed to bolster Latin America’s biopharmaceutical sector. By integrating a Contract Research Organization (CRO), a Scientific and Technological Park, and plans for an Advanced Center for Translational Medicine, the program is contributing to the national life sciences industry. Key projects include: Through projects hosted with Brazilian institutions, the program seeks to attract foreign investment, aiming to position Brazil as a biopharmaceutical hub. This collaborative vision strengthens access to healthcare while advancing economic growth and global visibility for the region. Note: Featured image is the Sudene building in Pernambuco, Brazil. The building has been provided to support International Companies coming to Brazil under the Peixe Rosa Program.
Feasibility Work on Collaboration Pathways for Brazil’s Biopharmaceutical Sector
Uniting Local and Global Expertise to Address Healthcare Challenges and Foster Innovation Exploratory collaboration frameworks have been evaluated to assess pathways for strengthening Brazil’s domestic biopharmaceutical manufacturing capabilities, with a particular focus on active pharmaceutical ingredients (APIs), technology transfer models, and long-term industrial development. This feasibility work related to a PDP application formed a part of our broader commitment to evaluating resilient pharmaceutical supply-chain strategies. These early-stage discussions brought together academic, technical, and private-sector perspectives to examine how public–private collaboration mechanisms might address structural gaps in supply chains, research translation, and domestic production capacity. The work emphasized governance design, institutional alignment, and sequencing considerations rather than transactional outcomes. The initiative formed part of a broader assessment of Brazil’s life sciences ecosystem and its potential integration with international manufacturing, research, and capital markets platforms. While no formal partnership or program approval resulted from this exploratory phase, the insights gained contributed to the evolution of a wider, multi-jurisdictional platform strategy. This work remains part of the project’s background research informing future pathways for industrial collaboration, subject to regulatory alignment, institutional participation, and appropriate timing. Cite: Brazil Press on University Initiative to Produce API